NDC 50090-2340

ODEFSEY

Emtricitabine, Rilpivirine, And Tenofovir Alafenamide

ODEFSEY is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by A-s Medication Solutions. The primary component is Emtricitabine; Rilpivirine Hydrochloride; Tenofovir Alafenamide Fumarate.

Product ID50090-2340_26120f57-70c4-4368-81de-9167e306a0a4
NDC50090-2340
Product TypeHuman Prescription Drug
Proprietary NameODEFSEY
Generic NameEmtricitabine, Rilpivirine, And Tenofovir Alafenamide
Dosage FormTablet
Route of AdministrationORAL
Marketing Start Date2016-03-01
Marketing CategoryNDA / NDA
Application NumberNDA208351
Labeler NameA-S Medication Solutions
Substance NameEMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE
Active Ingredient Strength200 mg/1; mg/1; mg/1
Pharm ClassesNucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA],Non-Nucleoside Analog [EXT],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [EXT],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
NDC Exclude FlagN
Listing Certified Through2019-12-31

Packaging

NDC 50090-2340-0

30 TABLET in 1 BOTTLE, PLASTIC (50090-2340-0)
Marketing Start Date2016-04-04
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 50090-2340-0 [50090234000]

ODEFSEY TABLET
Marketing CategoryNDA
Application NumberNDA208351
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2016-04-04
Inactivation Date2020-01-31

Drug Details

Active Ingredients

IngredientStrength
EMTRICITABINE200 mg/1

OpenFDA Data

SPL SET ID:f8689541-6526-47a5-9ff5-b8fc39ef4099
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 1741733
  • 1741739
  • Pharmacological Class

    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Non-Nucleoside Analog [EXT]
    • Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
    • Nucleoside Analog [EXT]
    • Nucleoside Reverse Transcriptase Inhibitors [MoA]
    • Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

    NDC Crossover Matching brand name "ODEFSEY" or generic name "Emtricitabine, Rilpivirine, And Tenofovir Alafenamide"

    NDCBrand NameGeneric Name
    50090-2340ODEFSEYemtricitabine, rilpivirine, and tenofovir alafenamide
    61958-2101ODEFSEYemtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide
    70518-0695ODEFSEYemtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide

    Trademark Results [ODEFSEY]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    ODEFSEY
    ODEFSEY
    86553716 4879988 Live/Registered
    Gilead Sciences Ireland UC
    2015-03-04

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.